Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies

por Chey, W. D., Dove, L. S., Andrae, D. A., Covington, P. S.
Publicado 2017

Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation

por Chang, L., Chey, W. D., Drossman, D., Losch‐Beridon, T., Wang, M., Lichtlen, P., Mareya, S.
Publicado 2016

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials...

por Schoenfeld, P., Pimentel, M., Chang, L., Lembo, A., Chey, W. D., Yu, J., Paterson, C., Bortey, E., Forbes, W. P.
Publicado 2014

Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders

por Tack, J, Camilleri, M, Chang, L, Chey, W D, Galligan, J J, Lacy, B E, Müller-Lissner, S, Quigley, E M M, Schuurkes, J, Maeyer, J H, Stanghellini, V
Publicado 2012